Injection, Trastuzumab-anns, Biosimilar, (Kanjinti), 10 mg (Q5117)

Name of the Procedure:

Common Name: Trastuzumab-anns Injection
Technical/Medical Term: Injection of trastuzumab-anns biosimilar (Kanjinti), 10 mg

Summary

This procedure involves administering a biosimilar drug called trastuzumab-anns to treat certain types of cancer. The injection helps in targeting and limiting the growth of cancer cells.

Purpose

Medical Conditions Addressed:

• Breast cancer
• Gastric cancer with HER2-overexpression

Goals/Expected Outcomes:

• To inhibit cancer cell growth
• To reduce tumor size
• To improve survival rates

Indications

Specific Symptoms/Conditions:

• HER2-positive metastatic breast cancer
• HER2-positive early breast cancer
• HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma

Patient Criteria:

• Patients diagnosed with HER2-positive cancers
• Determined suitable for treatment via biopsy and lab tests confirming HER2 positivity

Preparation

• Pre-procedure Instructions:

  • No fasting required
  • Continue regular medications unless advised otherwise

• Diagnostic Tests:

  • HER2 testing via biopsy
  • Blood tests to monitor overall health

Procedure Description

1. Before the Injection:

   • Patient is seated or lying in a comfortable position.
   • The injection site is cleaned.

2. During the Injection:

   • An intravenous (IV) line may be inserted into a vein in the arm.
   • The dosage (10 mg) of trastuzumab-anns is prepared.
   • The medication is slowly injected over a specified period, usually several minutes to hours.

3. After the Injection:

   • The IV line is removed.
   • The injection site is bandaged, if necessary.

Tools/Equipment:

• IV line
• Syringe
• Sterile vials of trastuzumab-anns (Kanjinti)

Anesthesia/Sedation:

• Typically not required, though mild sedatives may be provided for anxious patients.

Duration

The procedure typically takes about 30 minutes to a few hours, depending on the dosage and individual patient needs.

Setting

• Hospital oncology departments
• Outpatient clinics
• Specialized cancer treatment centers

Personnel

• Oncologist or specialized physician
• Oncology nurse
• Pharmacist (for drug preparation)
• Medical assistant

Risks and Complications

Common Risks:

• Injection site reactions (pain, redness, swelling)
• Fever
• Nausea

Rare Risks:

• Allergic reactions
• Heart problems (e.g., congestive heart failure)
• Serious infections

Management:

• Monitoring vital signs
• Immediate medical intervention for severe allergic reactions
• Regular cardiac evaluations

Benefits

• Slows or stops cancer growth
• Reduces tumor size
• Improves overall survival rates and quality of life

Realization Time:

• Benefits are usually realized within weeks to months of starting treatment.

Recovery

Post-procedure Care:

• Monitor for side effects
• Regular follow-up appointments for cancer progression monitoring

Recovery Time:

• No significant downtime; patients can usually return to normal activities shortly after

Restrictions:

• Avoid strenuous activities immediately after the injection
• Regular monitoring and possible adjustments to other medications

Alternatives

• Other HER2-targeted therapies (e.g., trastuzumab, pertuzumab)
• Chemotherapy
• Radiation therapy
• Surgery

Pros and Cons:

• Pros of Trastuzumab-anns: Effective targeted therapy, potentially fewer side effects compared to traditional chemotherapy
• Cons: Risk of heart problems, requires regular monitoring

Patient Experience

During the Procedure:

• Mild discomfort from IV insertion
• Some patients might feel anxious or fatigued

After the Procedure:

• Monitoring for any immediate reactions
• Pain management through prescribed medications, if needed

Comfort Measures:

• Encouragement to relax and rest
• Providing detailed post-care instructions to ensure a smooth recovery